Louise C Ivers1, David Kendrick, Karen Doucette. 1. Division of Social Medicine and Health Inequalities, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. livers@partners.org
Abstract
BACKGROUND: Despite the advent of effective combination antiretroviral drug therapy (ART) for the treatment of human immunodeficiency virus (HIV) infection, many doubt the feasibility of ART treatment programs in resource-poor settings. We performed a meta-analysis of the efficacy of ART programs in the developing world. We searched the Medline database with the index terms "HIV," "antiretroviral therapy," "CD4 count," "viral load," "experience," and "outcomes." A total of 201 abstracts were reviewed, and 25 articles were selected for detailed review. Ten observational studies with details on patient outcomes were ultimately included in the analysis. METHODS: Three readers independently extracted data from the articles. The details recorded included patient demographic characteristics, baseline CD4 cell counts, baseline HIV RNA viral loads, ART histories, outcomes, and timing of the outcome measure. RESULTS: The proportion of subjects with an undetectable HIV viral load provided the measure of treatment efficacy. A random-effects model weighted the proportion of patients with undetectable viral load at various time points during ART. The proportion was 0.697 (95% CI, 0.582-0.812) at month 6 and 0.573 (95% CI, 0.432-0.715) at month 12 of ART. The provision of medications free of charge to the patient was associated with a 29%-31% higher probability of having an undetectable viral load at months 6 and 12 than was the requirement that patients pay part or all of the cost of therapy. CONCLUSIONS: ART treatment programs in resource-poor settings have efficacy rates similar to those reported for developed countries. The provision of medications free of charge to the patient is associated with a significantly increased probability of virologic suppression at months 6 and 12 of ART.
BACKGROUND: Despite the advent of effective combination antiretroviral drug therapy (ART) for the treatment of human immunodeficiency virus (HIV) infection, many doubt the feasibility of ART treatment programs in resource-poor settings. We performed a meta-analysis of the efficacy of ART programs in the developing world. We searched the Medline database with the index terms "HIV," "antiretroviral therapy," "CD4 count," "viral load," "experience," and "outcomes." A total of 201 abstracts were reviewed, and 25 articles were selected for detailed review. Ten observational studies with details on patient outcomes were ultimately included in the analysis. METHODS: Three readers independently extracted data from the articles. The details recorded included patient demographic characteristics, baseline CD4 cell counts, baseline HIV RNA viral loads, ART histories, outcomes, and timing of the outcome measure. RESULTS: The proportion of subjects with an undetectable HIV viral load provided the measure of treatment efficacy. A random-effects model weighted the proportion of patients with undetectable viral load at various time points during ART. The proportion was 0.697 (95% CI, 0.582-0.812) at month 6 and 0.573 (95% CI, 0.432-0.715) at month 12 of ART. The provision of medications free of charge to the patient was associated with a 29%-31% higher probability of having an undetectable viral load at months 6 and 12 than was the requirement that patients pay part or all of the cost of therapy. CONCLUSIONS: ART treatment programs in resource-poor settings have efficacy rates similar to those reported for developed countries. The provision of medications free of charge to the patient is associated with a significantly increased probability of virologic suppression at months 6 and 12 of ART.
Authors: Leonardo Palombi; Maria Dorrucci; Ines Zimba; Paola Scarcella; Sandro Mancinelli; Ersilia Buonomo; Giovanni Guidotti; Maria C Marazzi; Giovanni Rezza Journal: Am J Trop Med Hyg Date: 2010-11 Impact factor: 2.345
Authors: Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer Journal: AIDS Date: 2008-03-30 Impact factor: 4.177
Authors: Martin W G Brinkhof; Matthias Egger; Andrew Boulle; Margaret May; Mina Hosseinipour; Eduardo Sprinz; Paula Braitstein; François Dabis; Peter Reiss; David R Bangsberg; Martin Rickenbach; Jose M Miro; Landon Myer; Amanda Mocroft; Denis Nash; Olivia Keiser; Margaret Pascoe; Stefaan van der Borght; Mauro Schechter Journal: Clin Infect Dis Date: 2007-10-22 Impact factor: 9.079
Authors: Olivia Keiser; Hannock Tweya; Paula Braitstein; François Dabis; Patrick MacPhail; Andrew Boulle; Denis Nash; Robin Wood; Ruedi Lüthi; Martin W G Brinkhof; Mauro Schechter; Matthias Egger Journal: Trop Med Int Health Date: 2009-12-09 Impact factor: 2.622
Authors: H Byakwaga; K Petoumenos; J Ananworanich; F Zhang; M A Boyd; T Sirisanthana; P C K Li; C Lee; C V Mean; V Saphonn; S F S Omar; S Pujari; P Phanuphak; P L Lim; N Kumarasamy; Y M A Chen; T P Merati; S Sungkanuparph; R Ditangco; S Oka; G Tau; J Zhou; M G Law; S Emery Journal: J Int Assoc Provid AIDS Care Date: 2013-02-19
Authors: Michael H Chung; Alison L Drake; Barbra A Richardson; Ashok Reddy; Joan Thiga; Samah R Sakr; James N Kiarie; Paul Yowakim; Grace C John-Stewart Journal: Curr HIV Res Date: 2009-07 Impact factor: 1.581